While reporting financial results for the fourth quarter on Friday, biopharmaceutical company Bristol-Myers Squibb Co. (BMY) initiated its adjusted earnings and revenue growth guidance for the full-year 2024.
For fiscal 2024, the company now projects adjusted earnings in a range of $7.10 to $7.40 per share on a worldwide total revenue growth in the low single-digits.
On average, 23 analysts polled by Thomson Reuters expect the company to report earnings of $7.00 per share on revenues growth of 1.9 percent to $45.58 billion for the year. Analysts' estimates typically exclude special items.
For the fourth quarter, the company reported net income attributable to Bristol-Myers Squibb of $1.76 billion or $0.87 per share, lower than $2.02 billion or $0.95 per share in the prior-year quarter. Excluding items, adjusted net earnings per share for the quarter was $1.70, compared to last year's $1.82.
Total revenues for the quarter declined 1 percent to $11.48 billion from $11.41 billion in the same quarter last year.
Analysts expected quarterly earnings of $1.53 per share on revenues of $11.19 billion for the quarter.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.